Replies to post #420936 on Anavex Life Sciences Corp (AVXL)

[crescentmotor]

Hopefully it will be a $1b run rate

Should easily approach that if AVXL can keep the competition at bay and AVXL captures only 20% of just the U.S. market. But these lofty numbers assume Blarcamesine doesn't have regulatory approval for AD because, if so, Blarcamesine would not be selling for $400,000 or more for Rett treatment.

Market size (per AVXL corporate presentation): U.S. 11,000; Europe 13,000; Asia 37,000; Global 350,000